2633.Hk
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products, primarily in the healthcare sector.
Business. The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products, primarily in the healthcare sector.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, focusing on the development, production, and sale of pharmaceutical products, primarily in the healthcare sector.
The company maintains a conservative capital structure, with a debt-to-equity ratio of 0.32, indicating a relatively low reliance on debt financing. Its liquidity position is characterized as medium, with a current ratio of 1.88, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's free cash flow of 136.75 million HKD is significantly lower than its operating cash flow of 526.78 million HKD, indicating that capital expenditures are consuming a large portion of its operating cash flow.
In terms of profitability, the company's return on equity (ROE) of 12.26% and return on assets (ROA) of 8.25% are strong indicators of efficient use of equity and assets. These figures are in line with the industry's preferred metrics, which emphasize ROE and ROA as key performance indicators. The company's gross profit margin of 43.93% and operating margin of 26.30% also suggest a healthy profitability profile, although a direct comparison to industry medians is not available in the provided data.
The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no geographic breakdown provided. This lack of diversification may pose a concentration risk, as the company's performance is heavily dependent on the success of its primary business segment. The absence of geographic data limits the ability to assess regional exposure and potential diversification benefits.
The company's growth trajectory is positive, with a current revenue of 1.58 billion HKD. While specific growth rates are not provided, the company's operating income of 414.60 million HKD and net income of 300.83 million HKD indicate a stable and profitable operation. Analysts have set a mean price target of 2.45 HKD, which is significantly higher than the current market price of 1.16 HKD, suggesting a potential for upward movement in the stock price.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt indicates a potential liquidity constraint. However, the company's low dilution risk suggests that there is minimal threat from share issuance that could dilute existing shareholders' equity. The absence of recent dilutive events and the low dilution potential further support this assessment.
Recent events and disclosures do not provide specific details on recent filings or transcripts. However, the company's financial performance and analyst estimates suggest a positive outlook. The mean recommendation of 1.00 (strong buy) from analysts indicates strong confidence in the company's future performance. The absence of recent negative events and the positive analyst sentiment contribute to a favorable investment outlook.
- The company has a strong return on equity (12.26%) and return on assets (8.25%), indicating efficient use of capital.
- The company's liquidity position is medium, with a current ratio of 1.88, suggesting adequate short-term financial health.
- The company's free cash flow is significantly lower than its operating cash flow, indicating high capital expenditures.
- Analysts have set a mean price target of 2.45 HKD, which is significantly higher than the current market price of 1.16 HKD.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 2633.HK Market data — financials · 2026-05-26
- Jacobson Pharma Corporation Ltd Market data — analyst estimates · 2026-05-26